Search
Cemivameran
go.drugbank.com/drugs/DB19415ApprovedIt is the active ingredient in the 2024-2025 formulation of Pfizer-BioNTech's Comirnaty vaccine.[L36030]
Velaglucerase alfa
go.drugbank.com/drugs/DB06720ApprovedAdditionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Cefmetazole
go.drugbank.com/drugs/DB00274ApprovedIt has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
Synonyms: (6R,7S)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidMF-300
go.drugbank.com/drugs/DB32060InvestigationalMF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.
Vinpocetine
go.drugbank.com/drugs/DB12131InvestigationalVinpocetine has been investigated for the treatment of Epilepsy.
Categories: Compounds used in a research, industrial, or household settingDitiocarb
go.drugbank.com/drugs/DB02520InvestigationalA chelating agent that has been used to mobilize toxic metals from the tissues of man and experimental animals. It is the main metabolite of DISULFIRAM.
Categories: Compounds used in a research, industrial, or household settingCGC-11047
go.drugbank.com/drugs/DB05722InvestigationalCGC-11047 is a polyamine analog designed to halt cell growth and induce apoptosis.
Isoflurane
go.drugbank.com/drugs/DB00753ApprovedInvestigationalVet approvedA stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
Human ciliary neurotrophic factor, recombinant (E. coli)
go.drugbank.com/drugs/DB17959ExperimentalHuman ciliary neurotrophic factor, recombinant was investigated for macular telangiectasia in two clinical trials. … The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia
Synonyms: Human ciliary neurotrophic factor, recombinant (E. coli)Stamulumab
go.drugbank.com/drugs/DB05915InvestigationalMYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.